Osteoclast-independent osteocyte dendrite defects in mice bearing the osteogenesis imperfecta-causing Sp7 R342C mutation

Abstract

Osteogenesis imperfecta (OI) is a group of diseases caused by defects in type I collagen processing which result in skeletal fragility. While these disorders have been regarded as defects in osteoblast function, the role of matrix-embedded osteocytes in OI pathogenesis remains largely unknown. Homozygous human SP7 (c.946  C >  T, R316C) mutation results in a recessive form of OI characterized by fragility fractures, low bone mineral density and osteocyte dendrite defects. To better understand how the OI-causing R316C mutation affects the function of SP7, we generated Sp7^R342C knock-in mice. Consistent with patient phenotypes, Sp7^R342C/R342C mice demonstrate increased cortical porosity and reduced cortical bone mineral density. Sp7^R342C/R342C mice show osteocyte dendrite defects, increased osteocyte apoptosis, and intracortical bone remodeling with ectopic intracortical osteoclasts and elevated osteocyte Tnfsf11 expression. Remarkably, these defects in osteocyte function contrast to only mild changes in mature osteoblast function, suggesting that this Sp7 mutation selectively interferes with the function of Sp7 in osteocytes and mature osteoblasts, but not during early stages of osteoblast differentiation. Osteocyte morphology changes in Sp7^R342C/R342C mice were not restored by inhibiting osteoclast formation, indicating that dendrite defects lie upstream of high intracortical osteoclast activity in this model. Moreover, transcriptomic profiling reveals that the expression of a core set osteocyte-enriched genes is highly dysregulated by the R342C mutation. Thus, this supports a model in which osteocyte dysfunction can drive OI pathogenesis and provides a valuable resource to test novel therapeutic approaches and to understand the osteocyte-specific role of SP7 in bone remodeling.

References

[1] ForlinoA, MariniJC. Osteogenesis imperfecta. Lancet, 2016, 387: 1657-1671

[2] MariniJC, et al.. Osteogenesis imperfecta. Nat. Rev. Dis. Prim., 2017, 317052

[3] JovanovicM, Guterman-RamG, MariniJC. Osteogenesis imperfecta: mechanisms and signaling pathways connecting classical and rare OI types. Endocr. Rev., 2021, 43: 61-90

[4] Wang, J. S. & Wein, M. N. Pathways controlling formation and maintenance of the osteocyte dendrite network. Curr. Osteoporos. Rep. 1–12 493–504 (2022).

[5] SarathchandraP, PopeFM, KayserMV, AliSY. A light and electron microscopic study of osteogenesis imperfecta bone samples, with reference to collagen chemistry and clinical phenotype. J. Pathol., 2000, 192: 385-395

[6] GrafeI, et al.. Excessive transforming growth factor-β signaling is a common mechanism in osteogenesis imperfecta. Nat. Med., 2014, 20: 670-675

[7] AndréG, et al.. Col1A-2 mutation in osteogenesis imperfecta mice contributes to long bone fragility by modifying cell-matrix organization. Int. J. Mol. Sci., 2023, 2417010

[8] DanyukovaT, et al.. Mice heterozygous for an osteogenesis imperfecta-linked MBTPS2 variant display a compromised subchondral osteocyte lacunocanalicular network associated with abnormal articular cartilage. Bone, 2023, 177116927

[9] MährM, et al.. Increased osteocyte lacunae density in the hypermineralized bone matrix of children with osteogenesis imperfecta type I. Int. J. Mol. Sci., 2021, 224508

[10] BlouinS, et al.. Hypermineralization and high osteocyte lacunar density in osteogenesis imperfecta type V bone indicate exuberant primary bone formation. J. Bone Miner. Res., 2017, 32: 1884-1892

[11] NakashimaK, et al.. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell, 2002, 108: 17-29

[12] XingW, GodwinC, PourteymoorS, MohanS. Conditional disruption of the osterix gene in chondrocytes during early postnatal growth impairs secondary ossification in the mouse tibial epiphysis. Bone Res., 2019, 724

[13] WangJS, et al.. Control of osteocyte dendrite formation by Sp7 and its target gene osteocrin. Nat. Commun., 2021, 126271

[14] LuY, et al.. DMP1-targeted Cre expression in odontoblasts and osteocytes. J. Dent. Res., 2007, 86: 320-325

[15] MoriishiT, et al.. Sp7 transgenic mice with a markedly impaired lacunocanalicular network induced sost and reduced bone mass by unloading. Int. J. Mol. Sci., 2022, 233173

[16] FiscalettiM, et al.. Novel variant in Sp7/Osx associated with recessive osteogenesis imperfecta with bone fragility and hearing impairment. Bone, 2018, 110: 66-75

[17] LapunzinaP, et al.. Identification of a frameshift mutation in Osterix in a patient with recessive osteogenesis imperfecta. Am. J. Hum. Genet., 2010, 87: 110-114

[18] LudwigK, et al.. Dominant osteogenesis imperfecta with low bone turnover caused by a heterozygous SP7 variant. Bone, 2022, 160116400

[19] Wang, J. S., Tokavanich, N. & Wein, M. N. SP7: from bone development to skeletal disease. Curr. Osteoporos. Rep.21, 241–252 (2023).

[20] Al-MutairiDA, et al.. A homozygous SP7/OSX mutation causes osteogenesis and dentinogenesis imperfecta with craniofacial anomalies. JBMR, 2024, 8ziae026

[21] OhtsukaM, et al.. i-GONAD: a robust method for in situ germline genome engineering using CRISPR nucleases. Genome Biol., 2018, 1925

[22] YoungC, et al.. A hypomorphic variant in the translocase of the outer mitochondrial membrane complex subunit TOMM7 causes short stature and developmental delay. Hum. Genet. Genom. Adv., 2023, 4100148

[23] YoultenSE, et al.. Osteocyte transcriptome mapping identifies a molecular landscape controlling skeletal homeostasis and susceptibility to skeletal disease. Nat. Commun., 2021, 122444

[24] MiiS, et al.. CD109 deficiency induces osteopenia with an osteoporosis‐like phenotype in vivo. Genes Cells, 2018, 23: 590-598

[25] ZhouS, et al.. Converging evidence from exome sequencing and common variants implicates target genes for osteoporosis. Nat. Genet., 2023, 55: 1277-1287

[26] KimH-N, et al.. Osteocyte RANKL is required for cortical bone loss with age and is induced by senescence. JCI Insight, 2020, 5e138815

[27] SchurmanCA, et al.. Aging impairs the osteocytic regulation of collagen integrity and bone quality. Bone Res., 2024, 1213

[28] BoyceBF, XingL. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res. Ther., 2007, 9S1

[29] BoyceBF, XingL. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch. Biochem. Biophys., 2008, 473: 139-146

[30] SimonetWS, et al.. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell, 1997, 89: 309-319

[31] Yoon, S.-H. et al. A parathyroid hormone/salt-inducible kinase signaling axis controls renal vitamin D activation and organismal calcium homeostasis. J. Clin. Investig.133, e163627 (2023).

[32] LimJ, GrafeI, AlexanderS, LeeB. Genetic causes and mechanisms of Osteogenesis Imperfecta. Bone, 2017, 102: 40-49

[33] Marom, R. et al. The IFITM5 mutation in osteogenesis imperfecta type V is associated with an ERK/SOX9-dependent osteoprogenitor differentiation defect. J. Clin. Investig. 134, e170369 (2024).

[34] CarrieroA, et al.. Altered lacunar and vascular porosity in osteogenesis imperfecta mouse bone as revealed by synchrotron tomography contributes to bone fragility. Bone, 2014, 61: 116-124

[35] WhyteMP, et al.. Juvenile Paget’s disease from heterozygous mutation of SP7 encoding osterix (Specificity Protein 7, Transcription Factor SP7). Bone, 2020, 137115364

[36] LuiJC, et al.. A neomorphic variant in SP7 alters sequence specificity and causes a high-turnover bone disorder. Nat. Commun., 2022, 13700

[37] OrwollES, et al.. Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. J. Clin. Investig., 2014, 124: 491-498

[38] GlorieuxFH, et al.. BPS804 anti‐sclerostin antibody in adults with moderate osteogenesis imperfecta: results of a randomized phase 2a Trial. J. Bone Miner. Res., 2017, 32: 1496-1504

[39] SongI-W, et al.. Targeting transforming growth factor- β (TGF-β) for treatment of osteogenesis imperfecta. J. Clin. Investig., 2022, 132e152571

[40] JepsenKJ, SilvaMJ, VashishthD, GuoXE, MeulenMC. van der. establishing biomechanical mechanisms in mouse models: practical guidelines for systematically evaluating phenotypic changes in the diaphyses of long bones. J. Bone Miner. Res., 2015, 30: 951-966

[41] DempsterDW, et al.. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res., 2013, 28: 2-17

[42] DoleNS, YeeCS, SchurmanCA, DallasSL, AllistonT. Skeletal development and repair, methods and protocols. Methods Mol. Biol., 2020, 2230: 303-323

[43] Kamel-ElSayedSA, Tiede-LewisLM, LuY, VenoPA, DallasSL. Novel approaches for two and three dimensional multiplexed imaging of osteocytes. Bone, 2015, 76: 129-140

[44] Tiede-LewisLM, et al.. Degeneration of the osteocyte network in the C57BL/6 mouse model of aging. Aging Albany, 2017, 9: 2190-2208

[45] SchurmanCA, VerbruggenSW, AllistonT. Disrupted osteocyte connectivity and pericellular fluid flow in bone with aging and defective TGF-β signaling. Proc. Natl. Acad. Sci. USA, 2021, 118e2023999118

[46] SchindelinJ, et al.. Fiji: an open-source platform for biological-image analysis. Nat. Methods, 2012, 9: 676-682

[47] DoubeM, et al.. BoneJ: free and extensible bone image analysis in ImageJ. Bone, 2010, 47: 1076-1079

[48] PatroR, DuggalG, LoveMI, IrizarryRA, KingsfordC. Salmon provides fast and bias-aware quantification of transcript expression. Nat. Methods, 2017, 14: 417-419

[49] LoveMI, HuberW, AndersS. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol., 2014, 15550

[50] ChenEY, et al.. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinform., 2013, 14128

[51] Maridas, D. E., Rendina-Ruedy, E., Le, P. T. & Rosen, C. J. Isolation, culture, and differentiation of bone marrow stromal cells and osteoclast progenitors from mice. J. Vis. Exp. https://doi.org/10.3791/56750 (2018).

Funding

U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)(K99AR081897)

U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases)(P01DK011794)

RIGHTS & PERMISSIONS

The Author(s)